HSCS RSI Chart
Last 7 days
-20.8%
Last 30 days
-31.0%
Last 90 days
-45.1%
Trailing 12 Months
-91.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 20.6K | 0 | 0 | 0 |
2023 | 9.3K | 5.2K | 0 | 5.8K |
2022 | 17.2K | 14.4K | 10.1K | 10.1K |
2021 | 0 | 25.6K | 22.8K | 20.0K |
Which funds bought or sold HSCS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | First Western Trust Bank | unchanged | - | -4,057 | 8,768 | -% |
May 15, 2024 | Cubist Systematic Strategies, LLC | new | - | 1,651 | 1,651 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | added | 63.89 | 635 | 5,908 | -% |
May 15, 2024 | CANTOR FITZGERALD, L. P. | unchanged | - | -2,705 | 5,845 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | new | - | 5,357 | 5,357 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -1.38 | -889 | 1,429 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | added | 298 | 9,106 | 14,389 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 4.00 | 4.00 | -% |
May 15, 2024 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | reduced | -16.84 | -6,243 | 8,225 | -% |
May 15, 2024 | AE Wealth Management LLC | sold off | -100 | -10,326 | - | -% |
Unveiling Heart Test Laboratories, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Heart Test Laboratories, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
Heart Test Laboratories, Inc. News
Income Statement (Quarterly) | ||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 |
Revenue | 276.9% | 15.00 | 4.00 | - | 2.00 | - | 3.00 | 4.00 | 3.00 | - | 7.00 | - |
Cost Of Revenue | 200.1% | 5.00 | 2.00 | - | 760* | - | 2.00 | 1.00 | 854* | - | 6.00 | - |
Gross Profit | 326.0% | 10.00 | 2.00 | - | 1.00 | - | 1.00 | 3.00 | 2.00 | - | 2.00 | - |
Operating Expenses | -2.3% | 1,536 | 1,572 | 1,599 | 1,310 | 1,775 | 1,431 | 1,981 | 1,102 | 957 | 676 | - |
S&GA Expenses | 25.9% | 1,026 | 815 | 1,064 | 667 | 926 | 997 | 625 | 403 | 411 | 275 | - |
R&D Expenses | -32.7% | 510 | 757 | 534 | 643 | 849 | 434 | 1,356 | 699 | 546 | 401 | - |
Interest Expenses | -33.6% | 118 | 178 | 34.00 | 33.00 | 33.00 | 144 | 77.00 | 139 | 78.00 | 78.00 | - |
Net Income | 6.0% | -1,643 | -1,748 | -1,632 | -1,342 | -1,806 | -1,573 | -2,053 | -1,238 | -1,034 | -501 | - |
Net Income Margin | 70.1% | -311.02* | -1.04 | -1.23 | -728.58* | -661.26* | -584.77* | -335.93* | -142.73* | -122.68* | -107.57* | -95.77* |
Free Cashflow | -117.2% | -2,150 | -990 | -1,869 | -1,023 | -1,080 | -1,818 | -1,192 | -966 | - | - | - |
Balance Sheet | ||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2021Q2 |
Assets | 356.0% | 10,801 | 2,368 | 2,598 | 3,287 | 3,480 | 4,771 | 5,567 | 2,089 | 1,927 |
Current Assets | 379.6% | 8,691 | 1,812 | 2,029 | 2,697 | 2,870 | 4,127 | 5,436 | 1,931 | 1,638 |
Cash Equivalents | 6966.3% | 7,076 | 100 | 576 | 1,660 | 1,931 | 3,076 | 4,078 | 918 | 723 |
Inventory | -0.7% | 670 | 675 | 676 | 676 | 677 | 678 | 678 | 674 | 751 |
Net PPE | 9.5% | 58.00 | 53.00 | 59.00 | 61.00 | 61.00 | 64.00 | 71.00 | 70.00 | 95.00 |
Liabilities | -46.1% | 2,167 | 4,018 | 3,118 | 3,057 | 3,738 | 3,688 | 2,680 | 8,145 | 3,837 |
Current Liabilities | -51.7% | 1,706 | 3,531 | 1,898 | 1,833 | 1,985 | 3,139 | 1,542 | 3,471 | 1,114 |
Shareholder's Equity | - | 8,634 | - | - | 231 | - | 1,083 | 2,887 | - | - |
Retained Earnings | -2.6% | -65,516 | -63,872 | -62,100 | -60,800 | -59,124 | -57,800 | -56,000 | -54,400 | -49,574 |
Additional Paid-In Capital | 19.1% | 74,086 | 62,211 | 61,593 | 60,977 | 58,858 | 58,857 | 58,855 | 48,343 | 47,661 |
Shares Outstanding | 467.3% | 636 | 112 | 107 | 101 | 74.00 | 82.00 | 56.00 | 33.00 | 33.00 |
Cashflow (Quarterly) | |||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 |
Cashflow From Operations | -116.7% | -2,141 | -988 | -1,404 | -1,861 | -1,020 | -1,080 | -1,811 | -1,192 | -966 | -768 | -717 | - |
Share Based Compensation | -9.2% | 96.00 | 106 | 125 | 99.00 | 2.00 | 2.00 | 146 | -49.85 | 116 | 834* | 2.00 | - |
Cashflow From Investing | -350.5% | -8.79 | -1.95 | -4.91 | -7.59 | -3.47 | - | -7.25 | - | - | - | - | - |
Cashflow From Financing | 1673.4% | 9,127 | 515 | 324 | 1,599 | -121 | -116 | 5,173 | 782 | 1,924 | - | - | - |
Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Jan. 31, 2024 | Jan. 31, 2023 | Jan. 31, 2024 | Jan. 31, 2023 | |
Income Statement [Abstract] | ||||
Revenue | $ 14,700 | $ 1,950 | $ 18,600 | $ 5,150 |
Cost of sales | 4,561 | 760 | 6,081 | 2,796 |
Gross margin | 10,139 | 1,190 | 12,519 | 2,354 |
Operating expenses: | ||||
Research and development | 509,507 | 643,258 | 1,832,442 | 1,926,432 |
Selling, general and administrative | 1,026,014 | 667,235 | 2,606,057 | 2,590,227 |
Total operating expenses | 1,535,521 | 1,310,493 | 4,438,499 | 4,516,659 |
Loss from operations | (1,525,382) | (1,309,303) | (4,425,980) | (4,514,305) |
Other income (expense) | ||||
Interest expense | (118,445) | (32,805) | (333,143) | (209,217) |
Other expense | (7) | |||
Other income | 16 | 0 | 79 | 1,593 |
Total other (expense) income | (118,429) | (32,812) | (333,064) | (207,624) |
Net loss | $ (1,643,811) | $ (1,342,115) | $ (4,759,044) | $ (4,721,929) |
Net loss per share, basic | $ (0.03) | $ (0.16) | $ (0.19) | $ (0.64) |
Net loss per share, diluted | $ (0.03) | $ (0.16) | $ (0.19) | $ (0.64) |
Weighted average common shares outstanding, basic | 53,792,741 | 8,240,798 | 25,201,024 | 7,371,764 |
Weighted average common shares outstanding, diluted | 53,792,741 | 8,240,798 | 25,201,024 | 7,371,764 |
Condensed Balance Sheets - USD ($) | Jan. 31, 2024 | Apr. 30, 2023 |
---|---|---|
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 7,076,497 | $ 1,660,467 |
Accounts receivable | 14,700 | |
Inventory | 670,278 | 676,359 |
Prepaid expenses | 233,322 | 143,460 |
Other current assets | 40,374 | 40,374 |
Deferred offering costs | 655,579 | 175,921 |
Total current assets | 8,690,750 | 2,696,581 |
Property and equipment, net | 58,393 | 61,428 |
Intangible assets, net | 1,568,818 | |
Right-of-use assets, net | 482,743 | 529,224 |
TOTAL ASSETS | 10,800,704 | 3,287,233 |
CURRENT LIABILITIES | ||
Accounts payable | 415,076 | 631,369 |
Accrued expenses | 584,427 | 623,391 |
Operating lease liabilities, current | 98,319 | 29,535 |
Current portion of notes payable | 500,000 | 500,000 |
Other current liabilities | 108,187 | 48,596 |
Total current liabilities | 1,706,009 | 1,832,891 |
LONG-TERM LIABILITIES | ||
Notes payable | 500,000 | |
Accrued expenses | 187,450 | |
Operating lease liabilities, long-term portion | 460,859 | 536,335 |
Total long-term liabilities | 460,859 | 1,223,785 |
TOTAL LIABILITIES | 2,166,868 | 3,056,676 |
COMMITMENTS AND CONTINGENCIES (NOTE 2, 5, and 8) | ||
STOCKHOLDERS' EQUITY | ||
Common Stock, $0.001 par value, 500,000,000 shares authorized; 63,611,630 shares issued and outstanding as of January 31, 2024 and 10,118,440 shares issued and outstanding as of April 30, 2023. | 63,611 | 10,118 |
Additional paid-in capital | 74,086,087 | 60,977,256 |
Accumulated deficit | (65,516,242) | (60,757,198) |
TOTAL STOCKHOLDERS' EQUITY | 8,633,836 | 230,557 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 10,800,704 | 3,287,233 |
Series A, B and C Convertible Preferred Stock | ||
STOCKHOLDERS' EQUITY | ||
Series A, B, and C convertible preferred stock, $0.001 par value, 20,000,000 shares authorized and 620,000 designated; 380,440 shares issued and outstanding as of January 31, 2024 and 380,871 shares issued and outstanding as of April 30, 2023. | $ 380 | $ 381 |